ArticleRegenerative biomaterials2021
A pH-responsive mesoporous silica nanoparticles-based drug delivery system with controlled release of andrographolide for OA treatment.
Article in Regenerative biomaterials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 61 citations in OpenAlex.
- Smart Nanodelivery Systems for Immunometabolic Modulation in Osteoarthritis.Exploration (Beijing, China) · 2026Review
- Stem Cell and Cell-Free Strategies for Osteoarthritis: Toward Durable Regenerative Therapies.Stem cells international · 2026Review
- Engineered Nanomaterials for Drug Delivery in Temporomandibular Joint Osteoarthritis: Translational Insights and Current Advances.International journal of nanomedicine · 2026Review
- Intra-Articular Injection in Wistar Rats: Standardization and Experimental Validation of a Precise Protocol for Nanomaterial Administration.Nanomaterials (Basel, Switzerland) · 2025Article
- Multifunctional injectable GelMA hydrogel incorporating Icariin-loaded Mesoporous silica nanoparticles to promote osseointegration.iScience · 2025Article
- Natural products in the treatment of osteoarthritis: Current status and prospects.Journal of orthopaedic translation · 2025Review
- Osteoarthritis: Mechanisms and Therapeutic Advances.MedComm · 2025Review
- Injectable sustainable andrographolide-releasing hydrogel for long-lasting alleviation of osteoarthritis and regulation of chondrocyte autophagy via PRKCA/EGFR.Materials today. Bio · 2025Article
- A review of nanomaterials in osteoarthritis treatment and immune modulation.Regenerative biomaterials · 2025Review
- Therapeutic Controlled Release Strategies for Human Osteoarthritis.Advanced healthcare materials · 2025Review
- Nanomaterial-Based Drug Delivery Systems Targeting Functional Cells for Osteoarthritis Treatment: Mechanisms, Challenges and Future Prospects.International journal of nanomedicine · 2025Review
- Controlled Stimulus-Responsive Delivery Systems for Osteoarthritis Treatment.International journal of molecular sciences · 2024Review
- Nanocomposite Hydrogels: A Promising Approach for the Treatment of Degenerative Joint Diseases.Small science · 2024Article
- Promoting chondrogenesis by targeted delivery to the degenerating cartilage in early treatment of osteoarthritis.Bioactive materials · 2024Article
- Recent Studies on Metal-Embedded Silica Nanoparticles for Biological Applications.Nanomaterials (Basel, Switzerland) · 2024Review
- Edge advances in nanodrug therapies for osteoarthritis treatment.Frontiers in pharmacology · 2024Review
- Advancements in pH-Responsive nanoparticles for osteoarthritis treatment: Opportunities and challenges.Frontiers in bioengineering and biotechnology · 2024Review
- A mesoporous polydopamine-derived nanomedicine for targeted and synergistic treatment of inflammatory bowel disease by pH-Responsive drug release and ROS scavenging.Materials today. Bio · 2023Article
- Recent Advances in Mesoporous Silica Nanoparticle-Mediated Drug Delivery for Breast Cancer Treatment.Pharmaceutics · 2023Review
- Advances in nanomaterial-based targeted drug delivery systems.Frontiers in bioengineering and biotechnology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Andrographolide (AG) has favorable anti-inflammatory and antioxidative capacity. However, it has low bioavailability due to high lipophilicity and can be easily cleared by the synovial fluid after intra-articular injection, leading to low therapeutic efficiency in osteoarthritis (OA). Herein, we designed a nano-sized pH-responsive drug delivery system (DDS) for OA treatment by using modified mesoporous silica nanoparticles (MSNs) with pH-responsive polyacrylic acid (PAA) for loading of AG to form AG@MSNs-PAA nanoplatform. The nanoparticles have uniform size (∼120 nm), high drug loading efficiency (22.38 ± 0.71%) and pH-responsive properties, beneficial to sustained release in OA environment. Compared with AG, AG@MSNs-PAA showed enhanced antiarthritic efficacy and chondro-protective capacity based on IL-1β-stimulated chondrocytes and anterior cruciate ligament transection-induced rat OA model, as demonstrated by lower expression of inflammatory factors and better prevention of proteoglycan loss. Therefore, the AG@MSNs-PAA nanoplatform may be developed as a promising OA-specific and on-demand DDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.